论文部分内容阅读
我科受卫生部委托参与了对卫生部武汉生物制品研究所抗癌新药康赛宁的Ⅲ期临床试验。共观察晚期肿瘤29例,摘取其中治疗完整的6例作报道。6例5男1女、年龄45～78y,平均60y。TNM分期Ⅲ～Ⅳ期,体力状态按PS分级标准为Ⅱ～Ⅲ级。经过康赛宁皮下注射1疗程后,近期疗效(按WHO评定标
My department by the Ministry of Health commissioned to participate in the Ministry of Health, Wuhan Institute of Biological Products Kangxin Ning new phase III clinical trials. A total of 29 cases of advanced tumors were observed, of whom 6 were intact for removal. 6 cases of 5 males and 1 females, aged 45 ~ 78y, an average of 60y. TNM staging Ⅲ ~ Ⅳ, physical state according to PS grading standards for Ⅱ ~ Ⅲ grade. After a second course of Cisseling subcutaneously, the curative effect (according to WHO evaluation standard